Brookie M. Best

机构：University of San Diego, University of California San Diego, Rady Children's Hospital-San Diego, University of Montana · ORCID：0000-0001-8569-2293

发表论文 188 篇 · 总被引 6550 次 · h-index 45

代表论文

• Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study (2024 · The Lancet HIV · 被引 30)
• Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study (2024 · The Lancet HIV · 被引 26)
• Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s (2023 · Antimicrobial Agents and Chemotherapy · 被引 16)
• Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study (2025 · The Lancet HIV · 被引 12)
• Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate–Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum (2024 · Clinical Infectious Diseases · 被引 12)
• Pharmacokinetics and Safety of Bictegravir in Pregnant and Postpartum Persons With HIV and Their Infants (2024 · JAIDS Journal of Acquired Immune Deficiency Syndromes · 被引 7)